(Q36632030)

15 August 2017

1 reference

title

Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism (English)

1 reference

15 August 2017

1 reference

1 reference

4

Darren K McGuire

1 reference

15 August 2017

2

James A De Lemos

1 reference

15 August 2017

Chetan B Patel

1

1 reference

PubMed ID

17058625

15 August 2017

Kathleen L Wyne

series ordinal

3

1 reference

PubMed ID

17058625

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Diabetes and Vascular Disease Research

15 August 2017

1 reference

15 August 2017

3

1 reference

15 August 2017

65-71

1 reference

15 August 2017

2

1 reference

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

15 August 2017

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Subclinical states of glucose intolerance and risk of death in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPARgamma and vascular inflammation: adding another piece to the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptors in endothelial cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Regional adiposity and morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Pioglitazone attenuates diet-induced hypertension in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Effects of pioglitazone on calcium channels in vascular smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Body mass index, diabetes, and C-reactive protein among U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2006.016

21 January 2018

Identifiers

DOI

10.3132/DVDR.2006.016

1 reference

15 August 2017

1 reference

PubMed ID

17058625